HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
Committee Members
Thomas J. Webster
Mansfield Bioincubator, United States
Consolato M Sergi
University of Ottawa, Canada
Sergey Suchkov
The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Saad Tayyab
UCSI University, Malaysia PDDS 2024 Speakers
Andreas M Papas
Antares Health Products, United States
Luis Jesus Villarreal Gomez
FCITEC - Universidad Autónoma de Baja California, Mexico
Thomas Ullrich
Novartis Biomedical Research, Switzerland
Afonin S.M
National Research University of Electronic Technology, Russian Federation
Miroslav Radenkovic
University of Belgrade, Serbia
Priya Hays
Hays Documentation Specialists, LLC, United StatesSubmit your abstract Today
Important Alert:
X Please be aware of fraudulent communication claiming to collect conference fees through unauthorized means, including cloned email addresses and phone numbers. Magnus Group advises all attendees to only process payments through our official event website and report any suspicious activity to [email protected]
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Photodegradation of two pharmaceutical namely levofloxacin and atorvastatin via Chitosan/Ag/TiO2 3D printed scaffold
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Preparation and characterization of fibers crafted from PCL/PVP-ChAgG, coupled with investigating their suitability as wound dressings.
Luis Jesus Villarreal Gomez, FCITEC - Universidad Autónoma de Baja California, Mexico
Title : Is your drug delivery formulation harming the environment ? Approaches to both save human health and the environment
Thomas J. Webster, Mansfield Bioincubator, United States
Title : Unveiling the binding interactions of selected antimalarial drugs with major plasma transporter
Saad Tayyab, UCSI University, Malaysia
Title : Pharmacokinetic properties of TNX-102 SL, a sublingual formulation of cyclobenzaprine hydrochloride
Bruce Daugherty, Tonix Pharmaceuticals, United States
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Mannitol as eutectic forming agent for improved sublingual delivery of Cyclobenzaprine HCl
Marino Nebuloni, University of Insubria, Italy